medigraphic.com
Instituto Nacional de Salud Pública

2003, Número S3

<< Anterior Siguiente >>

salud publica mex 2003; 45 (S3)


Grupo colaborador del Estudio Morelos de VPH. Mejorando la detección oportuna del cáncer cervical en México: resultados del Estudio de VPH en Morelos

Flores Y, Bishai D, Lazcano E, Shah K, Lbrincz A, Hernández M, Salmerón J, Ferris D, Hernández P, Sherman ME, Ronnett BM, Carmona E, Antúnez A, Manzanares H, Uribe M, Pérez-Cuevas R, Leyva A, Yunes E

Idioma: Ingles.
Referencias bibliográficas: 72
Paginas: 388-399
Archivo PDF: 115.03 Kb.


RESUMEN

Objetivo. Describir algunos de los resultados del Estudio de VPH en Morelos. El objetivo principal del Estudio de VPH en Morelos es evaluar el uso de la prueba del virus de papiloma humano (VPH), en relación con la prueba de Papanicolaou, para el tamizaje de cáncer cervical. Material y métodos. El Estudio de VPH en Morelos actualmente se está llevando a cabo en México, para examinar la posibilidad de usar la prueba de VPH para la detección de cáncer cervical. Se evaluó el uso de la prueba de VPH en muestras auto-tomadas vaginales y en muestras cervicales tomadas por un clínico. Se comparó la aceptabilidad del uso de la prueba de VPH en muestras autotomadas al uso del Papanicolaou. También se realizó un análisis de costo-efectividad y de costo-beneficio. Resultados. Los resultados del Estudio de VPH en Morelos indican que la prueba de VPH tiene una mayor sensibilidad para detectar los casos de neoplasia intraepitelial cervical 2/3 y cáncer cervical que la prueba de Papanicolaou. Los resultados también indican una aceptabilidad menor al uso de la prueba de Papanicolaou que al uso de la prueba de VPH auto-tomada. Los resultados del análisis de costo-efectividad y el análisis de costo-beneficio indican que el tamizaje con la prueba de VPH en mujeres de 20-80 años de edad siempre es más costo-efectivo que el tamizaje con el Papanicolaou. Conclusiones. Nuestros resultados sugieren que la prueba del VPH (ya sea auto-tomada o clínica) podría ser utilizada en los programas de detección y prevención de cáncer cervical, como un complemento o un sustituto efectivo de la prueba de Papanicolaou.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Secretaría de Salud. Estadísticas de mortalidad relacionada con la salud reproductiva. México, 1997. (Indicadores). Salud Publica Mex 1999;41:138-46.

  2. Lazcano-Ponce EC, Nájera-Aguilar P, Buiatti E, Alonso-de Ruiz P, Kuri P, Cantoral L, et al. The cervical cancer screening program in Mexico: Problems with access and coverage. Cancer Causes Control 1997;8:698-704.

  3. Dirección General de Estadística I y E. Estadísticas sobre tumores malignos en México. Dirección General de Estadística, Informática y Evolución. Salud Publica Mex 1997;39:388-399.

  4. Hernández-Avila M, Lazcano-Ponce EC, Alonso-de Ruiz P, Romieu I. Evaluation of the cervical cancer screening program in Mexico: A population-based case-control study. Int J Epidemiol 1998;27:1-7.

  5. National Cancer Institute Workshop: The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. JAMA. 1989;262:931-934.

  6. Lazcano-Ponce EC, Rascón-Pacheco RA, Lozano-Ascencio R, Velasco-Mondragón HE. Mortality from cervical carcinoma in Mexico: Impact of screening, 1980-1990. Acta Cytol 1996;40:506-512.

  7. Secretaría de Salud. La Perspectiva de Género en la Salud. 1996.

  8. Salmerón-Castro J, Franco-Marina F, Salazar-Martínez E, Lazcano-Ponce EC. Panorama epidemiológico de la mortalidad por cáncer en el IMSS: 1990-1995. Salud Publica Mex 1997;39:266-273.

  9. Compendio del Registro Histopatológico de Neoplasias en México. Morbididad y Mortalidad Secretaría de Salud. 1a Edición. 1996:35-37.

  10. Lazcano-Ponce EC, Moss S, Alonso-de Ruiz P, Salmerón-Castro J, Hernández-Avila M. Cervical cancer screening in developing countries: Why is it ineffective? The case of Mexico. Arch Med Res. 1999;30:240-250.

  11. Lazcano-Ponce EC, Buiatti E, Nájera-Aguilar P, Alonso-de Ruiz P, Hernández-Avila M. Evaluation model of the Mexican national program for early cervical cancer detection and proposals for a new approach. Cancer Causes Control 1998;9:1-11.

  12. Hernández-Avila M, Lazcano-Ponce EC, Alonso-de Ruiz P, López- Carrillo L, Rojas-Martínez. Evaluación del programa de detección oportuna del cáncer del cuello uterino en la Ciudad de México: Un estudio epidemiológico de casos y controles con base poblacional. Gac Med Mex 1994;130:201-209.

  13. Lazcano-Ponce EC, Nájera-Aguilar P, Alonso-de Ruiz P, Buiatti E, Hernández-Avila M. Programa de detección oportuna de cáncer cervical en México: Diagnóstico situacional. Cancerología 1996;42:123-140.

  14. Lazcano-Ponce EC, Castro R, Allen B, Nájera-Aguilar P, Alonso-de Ruiz P, Hernández-Avila M. Barriers to early detection of cervicaluterine cancer in Mexico. J Womens Health 1999; 8(3):399-408.

  15. Mitchell MF, Tortolero-Luna G, Wright T, Sarkar A, Richards-Kortum R, Hong WK et al. Cervical human papillomavirus infection and intraepithelial neoplasia: A review. J Natl Cancer Inst Monogr 1996;(21):17-25. Review.

  16. Herrero R. Epidemiology of cervical cancer. Monogr Natl Cancer Inst 1996;21:1-6.

  17. Cuzick J, Meijer CJ, Walboomers JM. Screening for cervical cancer. Lancet 1998;351:1439-1440.

  18. Division of STD Prevention. Prevention of Genital HPV Infection and Sequelae: Report of an External Consultants’ Meeting. Department of Health and Human Services, Atlanta: Centers for Disease Control and Prevention (CDC), December 1999.

  19. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85:958-964.

  20. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al. Human papillomavirus is a necessary cause of invasive cancer worldwide. J Pathol 1999;189:12-19.

  21. Cuzick J, Human Papillomavirus testing for primary cervical cancer screening. JAMA. 2000;283:108-109.

  22. Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang YT et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002;287(18):2372-2381.

  23. Lörincz AT, Richart RM. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med 2003;127(8):959-968.

  24. Ferenczy A. Viral testing for genital human papillomavirus infections: Recent progress and clinical potentials. Int J Gynecol Cancer 1995;5:321-328.

  25. Richart RM. Screening: The next century. Cancer 1995;15;76(10 suppl):1919-1927.

  26. Hatch KD, Schneider A, Abdel-Nour MW. An evaluation of human papillomavirus testing for intermediate- and high-risk types as triage before coloposcopy. Am J Obstet Gynecol 1995;172:1150-1157.

  27. Cox JT, Schiffman MH, Winzelberg AJ, Patterson JM. An evaluation of human papillomavirus testing as part of referral to colposcopy clinics. Obstet Gynecol 1992;80:384-389.

  28. Lörincz, AT. Hybrid capture method for detection of human papilloma virus DNA in clinical specimens. Papillomavirus Report 1996;7:1-5.

  29. Wright TC, Wei Sun X, Koulos J. Comparison of management algorithms for the evaluation of women with low-grade cytologic abnormalities. Obstet Gynecol 1995;85:202-210.

  30. Serwadda D, Wawer MJ, Shah KV, Sewankambo NK, Daniel R, Li C et al. Use of a hybrid capture assay of self-collected vaginal swabs in rural Uganda for detection of human papillomavirus. J Infect Dis 1999;180:316-319.

  31. Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA. 2001;285(24):3107-3115.

  32. Cuzick J, Sasieni P, Davies P, Adams J, Normand C, Frater A et al. A systematic review of the role of human papillomavirus (HPV) testing within a cervical screening programme: summary and conclusions. Br J Cancer 2000;83:561-565.

  33. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3-8.

  34. Hippeläinen M, Syrjänen S, Hippeläinen M et al. Prevalence and risk factors of genital papillomavirus infections in healthy males: A study on Finnish conscripts. Sex Transm Dis 1993;20:321-328.

  35. Grussendorf-Conen EI, de Villiers EM, Gissmann L. Human papillomavirus genomes in penile smears of healthy men. (Letter) Lancet 1986; ii:1092.

  36. Palefsky JM, Barrasso R. HPV infection and disease in men. In: Human Papillomavirus II. Obstet Gynecol Clin 1996;23:895-915.

  37. Flores Y, Shah K, Lazcano E, Hernández M, Bishai D, Ferris D et al. Design and methods of the evaluation of an HPV-based cervical cancer screening strategy in Mexico: The Morelos HPV Study. Salud Publica Mex 2002;44(4):335-344.

  38. Lazcano EC, Herrero R, Muñoz N, Cruz A, Shah KV, Alonso P et al. Epidemiology of HPV infection among Mexican women with normal cytology. Int J Cancer 2001;91(3): 412-420.

  39. Herrero R, Hildesheim A, Bratti C, Sherman M, Hutchinson M, Morales J et al. A population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. JNCI 2000;92(6): 464-474.

  40. Lörincz A, Reid R, Jenson B, Greenberg M, Lancaster W, Kurman R. Human papillomavirus infection of the cervix: Relative risk associations of 15 common anogenital types. Obstet Gynecol 1992;79:328-37.

  41. Cuzick J, Terry G, Ho L, Hollingworth T, Anderson M. Type-specific human papillomavirus DNA in abnormal smears as a predictor of highgrade cervical intraepithelial neoplasia. Br J Cancer 1994;69:167-171.

  42. Remmink AJ, Walboomers JM, Helmerhorst TJ, Voorhorst FJ, Rozendaal L, Risse EK et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: Natural history up to 36 months. Int J Cancer 1995;61:306-311.

  43. Wallin KL, Wiklund F, Angstrom T, Bergman F, Stendahl U, Wadell G, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999;341:1633-1638.

  44. Zhang MZ, Borchardt KA, Li Z. Condyloma acuminatum. In: Borchardt KA, Nobel MA, eds. Sexually Transmitted Diseases. New York: CRC Press, 1997:271-282.

  45. Richart RM, Masood S, Syrjanen KJ, Vassilakos P, Kaufman RH, Olszewski WT, et al. Human papillomavirus IAC task force summary. Acta Cytol 1998;42:50-58.

  46. Sedlacek TV. Advances in the diagnosis and treatment of human papillomavirus infections. Clin Obstet Gynecol. 1999;42:206-220.

  47. Strand A, Rylander E. Human papillomavirus. Subclinical and atypical manifestations. Dermatol Clin 1998;16: 817-822.

  48. Moscicki AB, Shiboski S, Broering J, Powell K, Clayton L, Jay N et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998;132:277-284.

  49. Rome RM, Chanen W, Pagano R. The natural history of human papillomavirus (HPV) atypia of the cervix. Aust N Z J Obst Gynaecol 1987;27:287-290.

  50. World Health Organization. IARC Monograph on the Evaluation of Carcinogenic Risks to Humans: Human Papillomaviruses. Lyons: IARC, 1995; Vol. 64.

  51. Brinton LA, Epidemiology of cervical cancer—overview. In: Muñoz N, Bosch FX, Shah KV, Meheus A, eds. The Epidemiology of Cervical Cancer and Human Papillomavirus. Lyon: IARC, 1992.

  52. Ho GY, Burk DD, Klein S, Kadish AS, Chang CJ, Palan P et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-1371.

  53. Villa L. Human papillomaviruses and cervical cancer. Adv Cancer Res 1997;71:321-341.

  54. Muñoz N, Bosch FX, De Sanjosé S, Shah KV. The role of HPV in the etiology of cervical cancer. Mutation Res 1994;305:293-301.

  55. Lörincz A. Hybrid CaptureTM method for detection of human papillomavirus DNA in clinical specimens. Papillomavirus Rep 1996;7:1-5.

  56. Salmerón J, Lazcano EC, Lörincz A, Hernández M, Hernández P, Leyva A et al. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico. Cancer Causes Control 2003;14:505-512.

  57. Schiffman M, Herrero R, Hildesheim A, Sherman M, Bratti M, Wacholder S et al. HPV DNA testing in cervical cancer screening: Results from women in a high-risk province of Costa Rica. JAMA 2000;283:87-93.

  58. Womack SD, Chirenje ZM, Blumenthal PD, Gaffikin L, McGrath JA, Chipato T et al. Evaluation of a human papillomavirus assay in cervical screening in Zimbabwe. BJOG 2000;107:33-8.

  59. Wright TC, Denny L, Kuhn L, Pollack A, Lörincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000;283:81-86.

  60. Lin CT, Tseng CJ, Lai CH, Hsueh S, Huang HJ, Law KS. High-risk HPV DNA detection by Hybrid Capture II. An adjunctive test for mildly abnormal cytologic smears in women > or = 50 years of age. J Reprod Med 2000;45(4):345-350.

  61. Sellors JW, Lörincz AT, Mahony JB, Mielzynska I, Lytwyn A, Roth P et al. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions. CMAJ 2000;163:513-518.

  62. Fait G, Kupferminc MJ, Daniel Y, Geva E, Ron IG, Lessing JB et al. Contribution of human papillomavirus testing by hybrid capture in the triage of women with repeated abnormal pap smears before colposcopy referral. Gynecol Oncol 2000;79:177-180.

  63. Bergeron C, Jeannel D, Poveda J, Cassonnet P, Orth G. Human papillomavirus testing in women with mild cytologic atypia. Obstet Gynecol 2000;95:821-827.

  64. Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M et al. Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women. Br J Cancer 1999;80:1306-1311.

  65. Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I et al. HPV testing in primary screening of older women. Br J Cancer 1999;8:554-558.

  66. Ferris DG, Wright TC, Litaker MS, Richart RM, Lörincz AT, Xaio-Wei S et al. Comparison of two tests for detecting carcinogenic HPV in women with papanicolaou smear reports of ASCUS and LSIL. J Fam Pract 1998;46:136-141.

  67. Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidem Biomar 2000;9:945-951.

  68. 18th International Papillomavirus Conference. Charleston, SC, USA. January 9-15, 1999.

  69. Dzuba I, Yunes-Díaz E, Allen B, Flores Y, Lazcano-Ponce EC, Shah K et al. The acceptability of self-collected samples for HPV testing vs. the pap test as alternatives in cervical cancer screening. J Womens Health Gend Based Med 2002;11(3):265-275.

  70. Cuzick J, Sasieni P, Davies P, Adams J, Normand C, Frater A et al. A systematic review of the role of human papillomavirus testing within a cervical screening program. Health Technol Assess 1999;3(14):i-iv, 1-204.

  71. van Ballegooijen M, van den Akker-van Marle ME, Warmerdam PG, Meijer CJ, Walboomers JM, Habbema JD. Present evidence on the value of HPV testing for cervical cancer screening: a modelbased exploration of the (cost-) effectiveness. Br J Cancer 1997;76:651-657.

  72. Flores Y, Bishai d, Lörincz A, Lazcano E, Hernández M, Salmerón J, Shah K. Cost-effectiveness of HPV testing as compared to the Pap in Mexico. 20th International Papillomavirus Conference. Paris, France. October 4-9, 2002.




2020     |     www.medigraphic.com